Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

Completed

• Conditions: X-Linked Retinitis Pigmentosa

• Registration Number: NCT03314207
• Lead Sponsor: Applied Genetic Technologies Corp

Brief Summary

The purpose of this study is to evaluate subjects with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations in a clinical setting to fully characterize their condition, measure testing variability, and estimate rates of progression of clinical parameters.

Detailed Description

Males with a clinical diagnosis of X-linked retinitis pigmentosa (XLRP) caused by RPGR-ORF15 mutations will be asked to provide informed consent and will have a single blood or saliva sample obtained for DNA sequence analysis of genes known to cause XLRP, including the RPGR-ORF15 gene. All participants will be informed of the results of testing for these mutations. Those with qualifying mutations in the RPGR-ORF15 gene will be evaluated every 6 months for 3 years using a variety of non-invasive visual function tests to more fully characterize their clinical condition. Testing will include routine ophthalmic examinations and tests of visual acuity, perimetry, OCT, fundus imaging, and completion of quality of life questionnaires.

Study Timeline

• Study First Submitted: 2017-10-11
• Study First Submitted QC: 2017-10-17
• Study First Posted: 2017-10-19
• Study Start: 2017-12-01
• Primary Completion: 2022-02-10
• Study Completion: 2022-02-10
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-10
• Last Update Posted: 2023-01-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 14

Inclusion Criteria

• Male subjects with a clinical diagnosis of XLRP and a documented molecular diagnosis from a CLIA-certified laboratory of mutation within the ORF15 exon of the RPGR gene;
• At least 6 years of age;
• Willing and able to perform study procedures;
• Signed informed consent(s) obtained (and child assent where applicable).

Exclusion Criteria

• Pre-existing eye conditions that would interfere with interpretation of study endpoints (e.g. glaucoma, corneal or lenticular opacities, diabetic retinopathy, history of retinal detachment);
• Participating in an interventional research study of drugs or devices for treatment of XLRP or other retinal diseases;
• Monoocular participants
• Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease progression in subjects with XLRP	Day 0 - Month 36

Secondary Outcome Measures

Name	Time	Method
Disease progression using visual acuity testing	Day 0 - Month 36
Disease progression using perimetry	Day 0 - Month 36
Disease progression using OCT	Day 0 - Month 36
Disease progression using electroretinography	Day 0 - Month 36
Disease progression using the National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25) quality of life questionnaire	Day 0 - Month 36

Trial Locations

Locations (3)

Duke Eye Center, Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Casey Eye Institute, Oregon Health and Sciences University; 🇺🇸 Portland, Oregon, United States

Retina Foundation of the Southwest; 🇺🇸 Dallas, Texas, United States